Ortho Evra is approved as a once-a-week contraceptive for women. It is the first transdermal hormonal patch to be approved, as well as the first non-invasive form of birth control that, when used correctly, is 99 percent effective.
Ortho Evra is a one and three-quarter inch square patch that must be applied to the lower abdomen, buttocks, upper torso, or outer upper arm. A woman is able to swim, bathe, and exercise without the patch coming off. Each patch is worn for seven days before being replaced, for three weeks. The fourth week is treatment free, as with oral contraceptives.
The approval of Ortho Evra is supported by data from clinical trials, conducted in more than 3,000 women, that compared the patch to oral contraceptives. When Ortho Evra is used correctly, the chance of becoming pregnant is approximately one percent. This is comparable to correct usage of the pill.
Adverse events associated with the use of Ortho Evra may include (but are not limited to) the following:
Ortho Evra (norelgestromin/ethinyl estradiol) is a combination contraceptive that acts through supression of gonadotropins. The primary mechanism of action is the inhibition of ovulation, though other alterations include changes in the cervical mucus and endometrium. The patch delivers a steady flow of hormones through the skin and into the bloodstream.
For additional information on Ortho Evra, please visit Ortho Evra.
The Ortho_evra drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.